Wang, Junjian
Zou, June X
Xue, Xiaoqian
Cai, Demin
Zhang, Yan
Duan, Zhijian
Xiang, Qiuping
Yang, Joy C
Louie, Maggie C
Borowsky, Alexander D
Gao, Allen C
Evans, Christopher P
Lam, Kit S
Xu, Jianzhen
Kung, Hsing-Jien
Evans, Ronald M
Xu, Yong
Chen, Hong-Wu
Article History
Received: 31 December 2015
Accepted: 19 February 2016
First Online: 28 March 2016
Change Date: 22 April 2016
Change Type: Corrigendum
Change Details: In Figure 2a of the version of this article initially published online, one phenyl ring was inadvertently deleted from the chemical structure of compound SR2211. One affiliation of H.-W.C. (Veterans Affairs Northern California Health Care System–Mather, Mather, California, USA) was also inadvertently omitted. These errors have been corrected for the print, PDF and HTML versions of this article.
Change Date: 7 June 2016
Change Type: Correction
Change Details: Nat. Med.; doi:10.1038/nm.4070; corrected online 22 April 2016 In Figure 2a of the version of this article initially published online, one phenyl ring was inadvertently deleted from the chemical structure of compound SR2211. One affiliation of H.-W.C. (Veterans Affairs Northern California Health Care System–Mather, Mather, California, USA) was also inadvertently omitted.
Competing interests
: H.W.C., J.X.Z., J.W. and Y.X. are co-inventors of a patent application covering methods of treating cancer with ROR-γ inhibitors. The other authors declare no competing financial interests.